Gilead Sciences Inc. said a late-stage study for selonsertib aimed at treating the progressive fatty liver disease NASH failed to meet the key experimental drug’s main goal, sending the company’s shares down 4.6 percent.
Sangamo Therapeutics Inc.’s shares sank 27 percent after the company’s gene-editing drug failed to show promise in an early-stage trial testing for patients with ultra-rare disorders.
Eli Lilly embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen.
Argenx and Halozyme Therapeutics signed a global collaboration and license deal that allows Argenx to use Halozyme’s Enhanze drug delivery technology to develop multiple products.
Merck & Co.’s cancer immumotherapy Keytruda compiled sales that topped $2 billion in a quarter for the first time, exceeding Wall Street’s lofty estimates and sending the company’s shares up.
Novo Nordisk reported solid growth for the company’s new diabetes drug and will submit a tablet version – a key growth hope – for U.S. approval in first-quarter 2019, lifting the Danish drugmaker’s shares.
Celgene Corp. – which is being bought by Bristol-Myers Squibb Co. – reported a better-than-expected fourth-quarter 2018 profit, driven mainly by higher sales of the psoriasis drug Otezla.
Amgen Inc. reported fourth-quarter 2018 profit that easily surpassed expectations as sales rose and tax expense fell, but competition for the company’s older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.
Allergan Plc forecast 2019 revenue below expectations on looming competition for some of the company’s top drugs, and shelved plans to sell the women’s health business.
CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.